Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;37(1):183-202.
doi: 10.1016/j.hoc.2022.08.017.

Multidisciplinary Management of Brain Metastasis from Breast Cancer

Dario Trapani  1 , Ayal A Aizer  2 , Nancy U Lin  3
Affiliations
Review

Multidisciplinary Management of Brain Metastasis from Breast Cancer

Dario Trapani et al. Hematol Oncol Clin North Am. 2023 Feb.

Abstract

The management of patients with breast cancer and brain metastases (BMs) is exquisitely multidisciplinary. Patients presenting with a symptomatic BM may be offered neurosurgical resection, followed by radiation. Stereotactic radiosurgery (SRS) is preferred over whole-brain radiotherapy (WBRT) in most patients presenting with a limited number of BMs, whereas WBRT with hippocampal-sparing and concomitant memantine is preferred for patients with multiple BMs. There is a growing role for systemic therapy, in some cases in lieu of local therapy, particularly in patients with HER2+ breast cancer.

Keywords: Brain metastases; Breast cancer; Multidisciplinary care; Multimodal treatments.

PubMed Disclaimer

Conflict of interest statement

Disclosure D. Trapani has no potential conflict to report. A.A. Aizer reports research funding from Varian Medical Systems and NH TherAguix and consulting/advisory board fees from Novartis and Seagen. N.U. Lin reports research funding from Genentech, Merck, Pfizer, Seattle Genetics, AstraZeneca, Zion Pharmaceuticals, and Olema Pharmaceuticals; honoraria for consulting/ad boards from Pfizer, Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Prelude Therapeutics, Denali Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, and Artera Inc; and royalties from UpToDate.

Similar articles

See all similar articles

Cited by